ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy With Concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Nelfinavir (Primary) ; Nivolumab (Primary) ; Atezolizumab; Pembrolizumab
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Therapeutic Use
- 15 May 2019 Status changed from recruiting to suspended.
- 31 Aug 2018 Biomarkers information updated
- 12 Jun 2017 Status changed from not yet recruiting to recruiting.